Chat with us, powered by LiveChat

 Speaker Profile

Ph.D., Director, NIH

Biography
Philip E. Castle, Ph.D., M.P.H., was appointed Director of the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) in July 2020. In this role, Dr. Castle oversees the conduct and support of research in cancer prevention, early detection, and screening, and prevention and management of symptoms and toxicities in cancer patients. DCP also is the home of the NCI Cancer Prevention Fellowship Program (CPFP), which trains future leaders in the field of cancer prevention and control, and from which Dr. Castle received his public health training from 1999 to 2002. Dr. Castle earned a Ph.D. in Biophysics in 1995 and, in conjunction with his training in the CPFP, a Master’s in Public Health in 2000, both at The Johns Hopkins University, Baltimore, Maryland. Most recently, Dr. Castle was a tenured professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine, Bronx, New York, and a visiting professor at institutions in Singapore, China and Australia. Dr. Castle was previously the Chief Scientific Officer of the American Society for Clinical Pathology. Dr. Castle has been a principal investigator for more than 15 years, initiating, conducting, and leading several large NCI molecular and clinical epidemiologic research studies in the U.S. and internationally, including the Mississippi Delta Project; the HPV (Human Papillomavirus) Persistence and Progression Cohort and the Guidelines Cohort at Kaiser Permanente Northern California (KPNC); and the Anal Cancer Screening Study. Dr. Castle worked in the NCI Division of Cancer Epidemiology and Genetics (DCEG) as a fellow, investigator, and then senior investigator from 2002 through 2010. He has co-authored more than 400 published articles on HPV and cervical and anogenital cancers and other cancer-related research. Dr. Castle was named NCI Cancer Prevention Fellowship Distinguished Alumnus in 2017 and was honored with the Arthur S. Flemming Award for Government Service in Applied Science, Engineering, and Mathematics in 2010. Dr. Castle has received many professional honors and recognitions, which can be viewed in his full curriculum vitae (PDF, 819 KB), and his publications. Dr. Castle also rejoins the NCI as a senior investigator with DCEG, focused on discovery, development, and evaluation/validation of new technologies for the prevention of cancer. His professional interests include health disparities, science and translation of cancer prevention strategies, cancer screening, health services research and delivery, epidemiology of HPV and cervical/anogenital cancers, international health, and evidence-based medicine. Dr. Castle is conducting research studies on cancer screening and prevention in Mozambique, Rwanda, and India as well as continuing his work with KPNC.


 Session Abstract – PMWC 2027 Silicon Valley

Track 3: Precision Dx - Jan 27 9.00 A.M.-5.00 P.M.


Track Chair:
Victor Velculescu, Johns Hopkins University

PMWC Award Ceremony
• Daniel De Carvalho, University of Toronto

From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Stephen Master, CHOP/U Penn
• Gordon Sanghera, Oxford Nanopore Technologies

Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Minetta Liu, Natera
• Rita Shaknovich, Agilent
• Ajay Gannerkote, Integrated DNA Tech

AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Eric Klein, GRAIL
• Sarah Moseley, DELFI Diagnostics
• Samuel Levy, ClearNote Health

Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Ron Andrews, Dxcover
• Pankaj Vats, NVIDIA
• Paul Shi, Amgen Fragmentomics for Early Detection: End Motifs and Library Prep
• Christopher Troll, Claret Bioscience

Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Paolo Di Domenico, Allelica

AI-Driven Metagenomic and Host RNA Profiling for Precision Diagnosis of Infections
• Charles Chiu, UCSF

AI-Driven Host–Pathogen Signatures from Plasma cfDNA: Bridging Infection Biology and Early Diagnostics
• Sivan Bercovici, Karius

Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection: AI-Driven Signal Profiling
• John Sninsky, CellMax Life

Overcoming Limits of Traditional cfDNA Assays Using Active Chromatin
• Diana Abdueva, Aqtual

Whole-genome methylome-based early cancer signal detection
• Sally Mackenzie, EpiMethyl Analytics

BrainSee Sees the Brain: FDA-Approved AI for Predicting Modifiable Risk of Developing Alzheimer’s Within Five Year
• Padideh Kamali-Zare, Darmiyan

×

Add Names/PO on Receipt

Request Atul Butte Company Competition Submission Form

Fields marked with an * are required

Contact Us:

Fields marked with an * are required 

Save $1311 By AUG. 13
PMWC 2027 Jan. 27-29 • Santa Clara
15 tracks • 400 speakers Co-hosted by Stanford/UCSF/Yale • Davos of PM
SAVE $1311 Rate increases AUG. 13 LOCK IN RATE

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required

Apply to Speak at PMWC Silicon Valley by AUG. 13TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.